What sector does Concord Biotech Limited belong to?

Concord Biotech Limited operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of CONCORDBIO?

As of the latest available quote, CONCORDBIO traded at ₹1,510.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of CONCORDBIO?

Concord Biotech Limited has a price-to-earnings (P/E) ratio of about 51.96. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of CONCORDBIO?

The market capitalisation of Concord Biotech Limited is approximately ₹15,752 Cr.

Is Concord Biotech Limited profitable?

For its latest reported financial year, Concord Biotech Limited recorded a net profit margin of about 24.55%.

Does CONCORDBIO pay a dividend?

Concord Biotech Limited does not currently show a dividend yield in our data.

What is the return on equity (ROE) of CONCORDBIO?

Concord Biotech Limited has a return on equity (ROE) of about 12.50%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of CONCORDBIO?

Over the past 52 weeks, CONCORDBIO has traded between a low of ₹987.00 and a high of ₹1,704.00.

Concord Biotech Limited

CONCORDBIO NSE Healthcare Pharmaceuticals

Nifty 500 Smallcap 250

₹1,510.00

+3.94%

Delayed · cached 15 min

Fair value analysis

CONCORDBIO

Concord Biotech Limited

₹1,452.80

Close used for this calculation

₹585.52Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

38/100

Profitability17/25

Returns5/25

Balance Sheet14/25

Efficiency2/25

Growth1/25

Average

Quality radar

Consensus fair value

₹585.52

Above FV

▼ -59.7% against the close used

Model range ₹69.83 – ₹890.36

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹69.83Fair value₹585.52Bull₹890.36

FairClose

52-week traded range

52W low ₹1,014.8052W high ₹1,695.10

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Concord Biotech Limited closed at ₹1,452.80, 148.1% above the consensus fair value of ₹585.52 drawn from 9 valuation models.

Financial DNA score 38/100 — Average. P/E of 56.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹220.38

-84.8%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=2.8%, r=10%, tg=3%, n=10yr

Graham Number

₹333.50

-77.0%

√(22.5 × EPS × BVPS)

EPS=24.94, BVPS=198.2 · outside Graham range (P/E 56.7, P/B 7.3) — asset-light, treat as a rough floor

Graham Formula

₹326.54

-77.5%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=2.8%, FD=7%

P/E Fair Value

₹890.36

-38.7%

EPS × 35.7x (sector P/E)

EPS=24.94, Sector P/E=35.7x

Peter Lynch (PEG)

₹69.83

-95.2%

EPS × Growth% (PEG = 1 is fair)

EPS=24.94, g=2.8%

EV/EBITDA

₹464.54

-68.0%

(EBITDA × 11.4x − Net Debt) ÷ Shares

EBITDA=4.42B

Book Value (P/B)

₹268.98

-81.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=198.2, ROE=12.5%, g=3%, r=10%

Reverse DCF

₹1,452.80

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 21.6% | Historical: 2.8%

Margin of Safety

₹332.02

-77.1%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=442.7, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer